<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003638</url>
  </required_header>
  <id_info>
    <org_study_id>812962</org_study_id>
    <nct_id>NCT02003638</nct_id>
  </id_info>
  <brief_title>Assessment Of Vascular Health After Niacin Therapy (AVANT)</brief_title>
  <acronym>AVANT</acronym>
  <official_title>A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY Fluorodeoxyglucose-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and
      favorably affect circulating levels of endothelial progenitor cells and microparticles in
      people with atherosclerotic disease on chronic statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Change from baseline in arterial Fluorodeoxyglucose (FDG) uptake assessed by FDG-PET/CT</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in circulating endothelial progenitor cells</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in endothelial-derived microparticles</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in platelet-derived microparticles</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in monocyte-derived microparticles</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Carotid Artery Disease</condition>
  <condition>Lower Extremity Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>niacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>niacin titrated up to 6 grams taken orally every day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>taken orally every day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <arm_group_label>niacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men age 55 years and above with coronary artery disease or women age 65 years and
             above with coronary artery disease OR Men age 45 years and above with both coronary
             artery disease and carotid or lower extremity peripheral artery disease or women age
             55 years and above with both coronary artery disease and carotid or lower extremity
             peripheral artery disease.

          -  Subjects must be on statin monotherapy, defined as a stable statin dose for at least
             12 weeks, with no anticipated need for further titration during the study period

        Exclusion Criteria:

          -  Anxiety or claustrophobia prohibiting imaging

          -  History of allergy to intravenous contrast, iodine, or shellfish

          -  Renal insufficiency

          -  History of allergy or severe intolerance to niacin

          -  History of diabetes mellitus or elevated fasting glucose

          -  Moderate to severe gout

          -  Peptic ulcer disease

          -  Acute coronary syndrome, transient ischemic attack or cerebrovascular accident, or
             acute limb ischemia in the preceding 12 months

          -  Heart failure or unstable angina pectoris

          -  Use of daily non-statin lipid-altering therapy prior to the initiation of study
             medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil deGoma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 5, 2013</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Emil deGoma</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
